- The Paul G. Allen Ebola Program awards a 12-month $2.1M grant to Chembio Diagnostics (CEMI +2.7%) to develop a point-of-care (POC) test to identify multiple life-threatening high fever-characterized (febrile) diseases.
- The company will use its Dual Path Platform (DPP) technology to develop a POC multiplex assay that will simultaneously detect Malaria, Dengue, Lassa, Marburg and Chikungunya.
- Chief Science and Technology Officer Javan Esfandiari says, "We are honored and excited that the Paul G. Allen Ebola Program has selected Chembio's patented DPP technology for the development of this highly-sensitive, specific and affordable rapid point-of-care multiplex assay for febrile illness. A small, cost-effective, battery-operated digital reader will be used to read the test results and report them electronically. We believe the DPP Fever Panel Assay and reader will become important tools in the battle against emerging disease worldwide."